Mark Edelstein

1.5k total citations
25 papers, 883 citations indexed

About

Mark Edelstein is a scholar working on Molecular Biology, Infectious Diseases and Virology. According to data from OpenAlex, Mark Edelstein has authored 25 papers receiving a total of 883 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Infectious Diseases and 8 papers in Virology. Recurrent topics in Mark Edelstein's work include HIV Research and Treatment (8 papers), HIV/AIDS drug development and treatment (8 papers) and Biochemical and Molecular Research (4 papers). Mark Edelstein is often cited by papers focused on HIV Research and Treatment (8 papers), HIV/AIDS drug development and treatment (8 papers) and Biochemical and Molecular Research (4 papers). Mark Edelstein collaborates with scholars based in United States, Netherlands and Slovakia. Mark Edelstein's co-authors include David S. Duch, Yoshisuke Ozaki, Charles A. Nichol, Joseph Chao, Larry A. Wolfe, Robert G. Ferris, Pat Wheelan, Wieslaw M. Kazmierski, Gail K. Smith and Andrew Spaltenstein and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Immunology.

In The Last Decade

Mark Edelstein

24 papers receiving 849 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Edelstein United States 14 326 219 167 145 123 25 883
Linda M. Thurmond United States 16 276 0.8× 141 0.6× 455 2.7× 215 1.5× 74 0.6× 31 1.5k
Clarence Ahlem United States 18 491 1.5× 56 0.3× 70 0.4× 125 0.9× 28 0.2× 38 1.0k
H.A. Lewis United States 18 1.1k 3.5× 111 0.5× 45 0.3× 107 0.7× 24 0.2× 32 1.6k
Katalin Goda Hungary 20 496 1.5× 78 0.4× 80 0.5× 495 3.4× 50 0.4× 45 1.1k
Mario Harvey Canada 21 473 1.5× 134 0.6× 60 0.4× 224 1.5× 51 0.4× 34 1.3k
Herbert E. Spiegel United States 17 356 1.1× 29 0.1× 210 1.3× 197 1.4× 28 0.2× 26 1.3k
Dirk Hendriks Belgium 27 899 2.8× 32 0.1× 103 0.6× 753 5.2× 47 0.4× 96 2.5k
Helmut Wachter Austria 10 156 0.5× 108 0.5× 67 0.4× 24 0.2× 45 0.4× 13 696
Shakti Gupta United States 17 717 2.2× 31 0.1× 347 2.1× 54 0.4× 56 0.5× 33 1.4k
Xiaojie Su China 15 188 0.6× 37 0.2× 171 1.0× 39 0.3× 19 0.2× 44 594

Countries citing papers authored by Mark Edelstein

Since Specialization
Citations

This map shows the geographic impact of Mark Edelstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Edelstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Edelstein more than expected).

Fields of papers citing papers by Mark Edelstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Edelstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Edelstein. The network helps show where Mark Edelstein may publish in the future.

Co-authorship network of co-authors of Mark Edelstein

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Edelstein. A scholar is included among the top collaborators of Mark Edelstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Edelstein. Mark Edelstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chong, Pek Y., Paul R. Sebahar, Dulce Garrido, et al.. (2012). Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Journal of Medicinal Chemistry. 55(23). 10601–10609. 43 indexed citations
2.
Duan, Maosheng, George A. Freeman, Robert G. Ferris, et al.. (2011). Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1. Bioorganic & Medicinal Chemistry Letters. 21(5). 1394–1398. 9 indexed citations
3.
Duan, Maosheng, Wieslaw M. Kazmierski, Pek Y. Chong, et al.. (2011). Discovery of novel pyridyl carboxamides as potent CCR5 antagonists and optimization of their pharmacokinetic profile in rats. Bioorganic & Medicinal Chemistry Letters. 21(21). 6470–6475. 9 indexed citations
4.
Duan, Maosheng, Wieslaw M. Kazmierski, Mark Edelstein, et al.. (2011). Discovery of a novel series of cyclic urea as potent CCR5 antagonists. Bioorganic & Medicinal Chemistry Letters. 21(21). 6381–6385. 9 indexed citations
5.
Duan, Maosheng, Mark Edelstein, Robert G. Ferris, et al.. (2010). Discovery of N-benzyl-N′-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (II): Modification of the acyl portion. Bioorganic & Medicinal Chemistry Letters. 20(24). 7401–7404. 6 indexed citations
6.
Duan, Maosheng, Mark Edelstein, Robert G. Ferris, et al.. (2010). Discovery of N-benzyl-N′-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): Optimization of the amine portion. Bioorganic & Medicinal Chemistry Letters. 20(24). 7397–7400. 9 indexed citations
7.
Jenkinson, Stephen, Michael M. Thomson, David McCoy, et al.. (2009). Blockade of X4-Tropic HIV-1 Cellular Entry by GSK812397, a Potent Noncompetitive CXCR4 Receptor Antagonist. Antimicrobial Agents and Chemotherapy. 54(2). 817–824. 55 indexed citations
8.
Muniz‐Medina, Vanessa, Stacey A. Jones, Jodi M. Maglich, et al.. (2008). The Relative Activity of “Function Sparing” HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property?. Molecular Pharmacology. 75(3). 490–501. 57 indexed citations
9.
Edelstein, Mark, Larry A. Wolfe, & David S. Duch. (1996). Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer.. PubMed. 23(2 Suppl 5). 41–7. 52 indexed citations
10.
11.
Schleien, Charles L., Jeffrey C. Hertz, J. Graham Thomas, Gwenn E. McLaughlin, & Mark Edelstein. (1995). PARENTAL ETHICAL DECISIONS IN THE PICU: IMPORTANCE OF RACIAL AND ETHNIC BACKGROUND. Critical Care Medicine. 23(Supplement). A195–A195. 1 indexed citations
12.
McDonald, S., et al.. (1994). Inside Writing: A Writer's Workbook. Medical Entomology and Zoology. 1 indexed citations
13.
Knowles, Richard G., et al.. (1991). The Role of Tryptophan and Kynurenine Transport in the Catabolism of Tryptophan Through Indoleamine 2,3-Dioxygenase. Advances in experimental medicine and biology. 294. 161–166. 6 indexed citations
14.
Kelley, James L., Ed W. McLean, Mark Edelstein, et al.. (1990). Synthesis and biological activity of an acyclic analog of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propyl]amino]benzoyl]-L-glutamic acid. Journal of Medicinal Chemistry. 33(2). 561–567. 24 indexed citations
15.
Nair, Muraleedharan G., Roy L. Kisliuk, Y. Gaumont, et al.. (1989). Folate analogs. 31. Synthesis of the reduced derivatives of 11-deazahomofolic acid, 10-methyl-11-deazahomofolic acid, and their evaluation as inhibitors of glycinamide ribonucleotide formyltransferase. Journal of Medicinal Chemistry. 32(6). 1277–1283. 11 indexed citations
16.
Ozaki, Yoshisuke, Mark Edelstein, & David S. Duch. (1988). Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma.. Proceedings of the National Academy of Sciences. 85(4). 1242–1246. 209 indexed citations
17.
Duch, David S., Cyrus J. Bacchi, Mark Edelstein, & Charles A. Nichol. (1984). Inhibitors of histamine metabolism in vitro and in vivo. Biochemical Pharmacology. 33(9). 1547–1553. 15 indexed citations
18.
Duch, David S., et al.. (1983). Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors.. Molecular Pharmacology. 24(1). 103–108. 23 indexed citations
19.
Duch, David S., et al.. (1982). Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase.. PubMed. 42(10). 3987–94. 55 indexed citations
20.
Duch, David S., Mark Edelstein, & Charles A. Nichol. (1980). Inhibition of Histamine-Metabolizing Enzymes and Elevation of Histamine Levels in Tissues by Lipid-Soluble Anticancer Folate Antagonists. Molecular Pharmacology. 18(1). 100–104. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Linda M. Thurmond Breakdown of academic impact, for papers by Clarence Ahlem Breakdown of academic impact, for papers by H.A. Lewis Breakdown of academic impact, for papers by Katalin Goda Breakdown of academic impact, for papers by Mario Harvey Breakdown of academic impact, for papers by Herbert E. Spiegel Breakdown of academic impact, for papers by Dirk Hendriks Breakdown of academic impact, for papers by Helmut Wachter Breakdown of academic impact, for papers by Shakti Gupta Breakdown of academic impact, for papers by Xiaojie Su
Rankless by CCL
2026